Computer Algorithms Automatically Detect Malaria in Stained Blood Smears
|
By LabMedica International staff writers Posted on 10 Aug 2015 |
|
Image: The Parasight platform: computer vision technology scans stained blood samples under a fluorescent microscope and detects the presence of malaria parasites in blood cells (Photo courtesy of Sight Diagnostics).
An Israeli startup company has developed a computerized platform that detects anomalies in stained blood cell samples—such as those infected by the malaria parasite—faster and more accurately than the human eye.
Sight Diagnostics or SightDx (Jerusalem, Israel) was initiated in 2011 with six million USD obtained from crowd funding and several innovation investors. This funding was used by a team comprising biologists, software experts, and engineers to develop vision-based algorithms to scan and analyze blood. Analysis was based on visible characteristics such as size, shape, fluorescence intensity, and morphology.
The algorithms were set to function within SightDx's Parasight platform, a high throughput instrument suitable for batch (up to 30 samples) and asynchronous loading. It was designed to be fully automated, simple to operate, and optimized for rapid testing and analysis.
The Parasight platform consists of a scanning and analyzing device as well as a sample preparation kit containing custom-built disposable plastic cartridges to create an efficient, standardized, and uniform version of the “thin blood smear”, that is easy to prepare within 15 seconds. These cartridges require only a small drop of blood that can be obtained with a finger-stick or from a tube. Parasight reports, in under three minutes, the diagnosis (Positive/Negative), parasitemia count (number of parasites per microliter), and speciation (determination of the specific species of malaria). Results are automatically transferred to the laboratory information system.
Trials using Parasight were conducted in several hospitals in India, South Africa, and France. Results showed that it was 99% accurate in sensitivity and 98% in specificity as compared to results of about 95% for human microscopists.
“Essentially, you try to do what the human eye does,” said Joseph Joel Pollak, CEO of Sight Diagnostics. “Computer vision-based devices have a camera, and the camera takes pictures of the blood. Then, algorithms analyze the scene.”
Related Links:
Sight Diagnostics
Sight Diagnostics or SightDx (Jerusalem, Israel) was initiated in 2011 with six million USD obtained from crowd funding and several innovation investors. This funding was used by a team comprising biologists, software experts, and engineers to develop vision-based algorithms to scan and analyze blood. Analysis was based on visible characteristics such as size, shape, fluorescence intensity, and morphology.
The algorithms were set to function within SightDx's Parasight platform, a high throughput instrument suitable for batch (up to 30 samples) and asynchronous loading. It was designed to be fully automated, simple to operate, and optimized for rapid testing and analysis.
The Parasight platform consists of a scanning and analyzing device as well as a sample preparation kit containing custom-built disposable plastic cartridges to create an efficient, standardized, and uniform version of the “thin blood smear”, that is easy to prepare within 15 seconds. These cartridges require only a small drop of blood that can be obtained with a finger-stick or from a tube. Parasight reports, in under three minutes, the diagnosis (Positive/Negative), parasitemia count (number of parasites per microliter), and speciation (determination of the specific species of malaria). Results are automatically transferred to the laboratory information system.
Trials using Parasight were conducted in several hospitals in India, South Africa, and France. Results showed that it was 99% accurate in sensitivity and 98% in specificity as compared to results of about 95% for human microscopists.
“Essentially, you try to do what the human eye does,” said Joseph Joel Pollak, CEO of Sight Diagnostics. “Computer vision-based devices have a camera, and the camera takes pictures of the blood. Then, algorithms analyze the scene.”
Related Links:
Sight Diagnostics
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Multi-Chamber Washer-Disinfector
WD 390
HPV Molecular Test
BD Onclarity HPV Assay
Latest Microbiology News
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read more
Molecular Diagnostics
view channel
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read more
Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
Adjuvant therapy decisions after curative surgery for colon cancer remain difficult, as conventional clinicopathologic factors often fail to capture residual disease risk. Liquid biopsy approaches that... Read more
Hematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more
Immunology
view channel
Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Pathology
view channel
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read more
FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
Clinical laboratories play a central role in guiding immunotherapy by reporting programmed death ligand-1 (PD‑L1) status across multiple solid tumors. Many sites are standardizing this work on fully automated... Read more
Technology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more
Industry
view channel
Diazyme Laboratories Acquires Carolina Liquid Chemistries
Diazyme Laboratories, Inc. (Poway, CA, USA), a diagnostics company developing enzyme and immunoassay-based test reagents, has acquired the business of Carolina Liquid Chemistries Corporation (CLC, Greensboro,... Read more
